Search

Displaying results 3441 - 3450 of 4300 in total
  1. Drug

    Imolamine

    go.drugbank.com/drugs/DB09284
    Investigational

    It is developed under the brand name Coremax by Novartis consumer health SA.

  2. Drug

    HLX70

    go.drugbank.com/drugs/DB16509
    Investigational

    The condition targeted by HLX70 in this study is COVID-19.

  3. Drug

    Thalagen

    go.drugbank.com/drugs/DB17714
    Experimental

    Thalagen is a branded product developed by San Rocco Therapeutics.

  4. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    It is being developed by Kalypsys.

  5. Drug

    Zotiraciclib

    go.drugbank.com/drugs/DB16656
    Investigational

    Zotiraciclib is under investigation in clinical trial NCT02942264 (Zotiraciclib (TG02) Plus Dose-dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide

  6. Drug

    Natural Killer Cell

    go.drugbank.com/drugs/DB15721
    Investigational

    Other techniques involve using umbilical cord blood (UCB) directly; these NK cells have heterogeneous CD56 expression but are considered suitable for immunotherapy.

  7. Drug

    Doxacurium

    go.drugbank.com/drugs/DB01135
    ApprovedWithdrawn

    Doxacurium chloride is a long-acting, nondepolarizing skeletal muscle relaxant for intravenous administration.

  8. Drug

    Carteolol

    go.drugbank.com/drugs/DB00521
    Approved

    A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

  9. Drug

    CCR5 mAb

    go.drugbank.com/drugs/DB05906
    Experimental

    It was generated by HGS using the Abgenix XenoMouse technology.

  10. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.